ABSTRACT
Fetal ECG monitoring is a routine clinical detection method that can reflect the changes of fetal heart in utero in real time. At present, most of the clinical fetal heart rate detection adopts the ultrasonic Doppler method, which is technically difficult and highly specialized in operation and expensive. This study introduces a fetal ECG detection system based on the maternal abdominal electrode method. The weak fetal ECG changes are sensed through the maternal abdominal electrode, and the mixed ECG signal is obtained through the corresponding amplification and filtering circuit. Finally, the obtained signal is passed through WiFi, transmitted to the host computer. The host computer uses the adaptive filtering algorithm to estimate the fetal ECG signal. The system has strong feasibility, low operation expertise, low cost, and is more convenient.
ABSTRACT
Objective To retrospectively analyze the clinical data of 47 young NSCLC patients mutation style of EGFR and PD-L1 expression in tumor cells, to understand their clinicopathological and molecular characteristics. Methods We enrolled 47 young (≤40 years old) patients confirmed as NSCLC who underwent surgical resection, and 94 old patients (≥60 years old) were matched as 1:2 by R language. EGFR mutation status was detected by ARMS-PCR, and the expression of PD-L1 was detected by immunohistochemistry. Results The median age of 47 young patients with NSCLC was 37 years old. The disease was more common in women and the majority type was adenocarcinoma. In youth group, the 19del and 20ins were more frequent, but the exon 21 L858R point mutation proportion was higher in elder group. The expression of PD-L1 was significantly increased in the solid predominant histological subtype. The PD-L1 expression in 19del patients was higher than that in the patients with L858R mutation in youth group. Conclusion The majority of young NSCLC patients are female, nonsmokers and suffered from adenocarcinoma cancer. The proportion of EGFR alteration in 19del and 20ins in youth group is higher than that in elder group. The positive rate of PD-L1 expression in solid predominant histological subtype is higher than that with other subtypes. The expression of PD-L1 in young patients with EGFR 19del is higher than that with L858R.
ABSTRACT
This study introduces a portable multi-channel EEG signal acquisition system. The system is mainly composed of EEG electrode connector, signal conditioning circuit, EEG acquisition part, main control MCU and power supply part. The low-power EEG acquisition front-end ADS1299 and STM32 are used to form the signal acquisition and data communication part. The collected EEG signal can be transmitted to the PC for real-time display. After relevant tests, the system has small volume, low power consumption, high signal-to-noise ratio, and meets the requirements of portable wearable medical devices.
Subject(s)
Electric Power Supplies , Electrodes , Electroencephalography , Signal Processing, Computer-Assisted , Signal-To-Noise RatioABSTRACT
Body temperature is an important physiological parameter of the human body and is used in medicine to reflect the physiological state and health status of the human body. At present, the commonly used clinical thermometers on the market are mainly divided into contact and non-contact types. Most of them are used for rapid body temperature measurement, and it is not easy to monitor body temperature changes in real time. This article introduces a new wearable wireless body temperature monitoring system based on NTC, which senses through NTC. The temperature changes are amplified and filtered, zeroed, and calibrated, and then the temperature data is uploaded to the mobile phone APP via Bluetooth in real time to achieve real-time accurate measurement of body temperature.
Subject(s)
Humans , Body Temperature , Cell Phone , Monitoring, Physiologic , Temperature , Wearable Electronic Devices , Wireless TechnologyABSTRACT
Body temperature is an essential physiological parameter. Conducting non-contact, fast and accurate measurement of temperature is increasing important under the background of COVID-19. The study introduces an infrared temperature measurement system based on the thermopile infrared temperature sensor ZTP-135SR. Extracting original temperature date of sensor, post-amplification and filter processing have been performed to ensure accuracy of the system. In addition, the temperature data of environmental compensation which obtained by polynomial fitting is added to the system to further improve measurement accuracy.
Subject(s)
Humans , Algorithms , Body Temperature , COVID-19 , Temperature , ThermometersABSTRACT
BACKGROUND@#Immune checkpoint inhibitor monotherapy is reported to have little effect in advanced non-small cell lung cancer (NSCLC) patients with driver oncogenes. However, recent studies have shown that some patients with driver genes are still benefit from combination immunotherapy after tyrosine kinase inhibitors (TKIs) drug resistance. The purpose of this study was to analyze the efficacy of posterior line immunotherapy in NSCLC patients with epidermal growth factor (EGFR) sensitive mutation, and to evaluate the value of immunotherapy in posterior line therapy in patients with advanced EGFR mutation.@*METHODS@#A total of 27 patients with EGFR mutation diagnosed in Beijing Chest Hospital, Capital Medical University from June 2018 to November 2020 were collected. After the progress of targeted therapy, they had received programmed cell death protein 1 (PD-1) checkpoint inhibitor combined with chemotherapy and anti-angiogenic drug therapy.@*RESULTS@#Of the 27 advanced NSCLC patients, 19 cases (70.4%) did not have T790M mutation. There were 8 cases (29.6%) with T790M point mutation. The total objective response rate (ORR) was 40.7%. Kaplan-Meier survival analysis showed that there was no statistically significant difference among different EGFR mutations (χ²=4.15, P=0.230). But progression-free survival (PFS) was significantly longer in patients without T790M mutation than in patients with T790M mutation (9.2 mon vs 3.3 mon, χ²=2.808, P=0.041), and the same trend was observed in patients with overall survival treated with the PD-1 inhibitor (12.2 mon vs 7.3 mon, χ²=3.22, P=0.062). ORR of patients without T790M was significantly better than that with T790M (52.63% vs 12.5%, P=0.045).@*CONCLUSIONS@#Patients with EGFR mutation can benefit from later-line combined immunotherapy. The patients with T790M mutation in the population of EGFR mutation had the worst effect of immunotherapy in the later line. Therefore, the follow-up treatment and whole-course management of these patients need to explore better treatment strategies to improve the benefit.